Search research articles
Contact Us
Filters
Showing results (1-10 of 85) with videos related to
Page
of 9
Sort By:
Archives of Physiology and Biochemistry
|
June 3, 2009
The insulin-like growth factor-I receptor as an oncogene
Haim Werner, Ilan Bruchim
BMC Medicine
|
January 7, 2010
Basic and clinical significance of IGF-I-induced signatures in cancer
Haim Werner, Ilan Bruchim
Expert Opinion on Therapeutic Targets
|
January 9, 2013
Targeting IGF-1 signaling pathways in gynecologic malignancies
Ilan Bruchim, Haim Werner
The Lancet. Oncology
|
November 28, 2012
IGF-1 and BRCA1 signalling pathways in familial cancer
Haim Werner, Ilan Bruchim
Frontiers in Endocrinology
|
June 7, 2014
The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches
Ilan Bruchim, Rive Sarfstein, Haim Werner
Expert Opinion on Therapeutic Targets
|
August 12, 2009
Targeting the IGF1 axis in cancer proliferation
Ilan Bruchim, Zohar Attias, Haim Werner
Gynecologic Oncology
|
September 10, 2002
Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer
Ilan Bruchim, Marco Altaras, Ami Fishman
Expert Opinion on Investigational Drugs
|
November 17, 2019
Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy
Haim Werner, Rive Sarfstein, Ilan Bruchim
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
October 24, 2012
Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
Ilan Bruchim, Osnat Jarchowsky-Dolberg, Ami Fishman
Molecular Cancer
|
February 20, 2018
Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway
Haim Werner, Shilhav Meisel-Sharon, Ilan Bruchim
Page
of 9
Search research articles
Search
Showing results (1-10 of 85) with videos related to
Sort By:
Page
of 9
Archives of Physiology and Biochemistry
|
June 3, 2009
The insulin-like growth factor-I receptor as an oncogene
Haim Werner, Ilan Bruchim
BMC Medicine
|
January 7, 2010
Basic and clinical significance of IGF-I-induced signatures in cancer
Haim Werner, Ilan Bruchim
Expert Opinion on Therapeutic Targets
|
January 9, 2013
Targeting IGF-1 signaling pathways in gynecologic malignancies
Ilan Bruchim, Haim Werner
The Lancet. Oncology
|
November 28, 2012
IGF-1 and BRCA1 signalling pathways in familial cancer
Haim Werner, Ilan Bruchim
Frontiers in Endocrinology
|
June 7, 2014
The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches
Ilan Bruchim, Rive Sarfstein, Haim Werner
Expert Opinion on Therapeutic Targets
|
August 12, 2009
Targeting the IGF1 axis in cancer proliferation
Ilan Bruchim, Zohar Attias, Haim Werner
Gynecologic Oncology
|
September 10, 2002
Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer
Ilan Bruchim, Marco Altaras, Ami Fishman
Expert Opinion on Investigational Drugs
|
November 17, 2019
Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy
Haim Werner, Rive Sarfstein, Ilan Bruchim
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
October 24, 2012
Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
Ilan Bruchim, Osnat Jarchowsky-Dolberg, Ami Fishman
Molecular Cancer
|
February 20, 2018
Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway
Haim Werner, Shilhav Meisel-Sharon, Ilan Bruchim
Page
of 9